Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration [PDF]
International Journal of Retina and Vitreous, 2021 Background To assess the morphological and functional outcome of intravitreal aflibercept following the treat and extend protocol compared to the fixed protocol for treatment of eyes with neovascular age-related macular degeneration.
Alaa Din Abdin +6 more
doaj +2 more sources
A simulation tool for better management of retinal services [PDF]
BMC Health Services Research, 2018 Background Advances in the management of retinal diseases have been fast-paced as new treatments become available, resulting in increasing numbers of patients receiving treatment in hospital retinal services. These patients require frequent and long-term
Eren Demir +3 more
doaj +4 more sources
Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema [PDF]
Scientific Reports, 2021 AbstractThis prospective, open-label, single-arm, non-randomized clinical trial, assessed the efficacy of a 2-year treat-and-extend (T&E) regimen involving intravitreal aflibercept injection (IAI), with the longest treatment interval set to 16 weeks, and adjunct focal/grid laser in diabetic macula edema (DME) patients.
Takao Hirano +12 more
openaire +6 more sources
Faricimab Treat-and-Extend for Diabetic Macular Edema [PDF]
OphthalmologyPurpose: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-andextend (T&E)-based regimen with up to every-16-week dosing in the YOSEMITE and RHINE (ClinicalTrials.govidentifiers, NCT03622580 and ...
WONG, T +2 more
core +4 more sources
Clinical outcome using a modified treat-and-extend protocol for neovascular age-related macular degeneration. [PDF]
BMJ Open Ophthalmol, 2022 Aim To compare outcome between patients treated using a modified treat-and-extend (mT&E) protocol and patients treated using a conventional T&E protocol. Methods A retrospective cohort study of two groups of treatment-naïve neovascular age ...
Vofo BN, Cnaany Y, Chowers I.
europepmc +4 more sources
A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration [PDF]
Frontiers in Medicine, 2022 PurposeTo compare the efficacy and safety of conbercept using a treat-and-extend (T&E) regimen vs. a pro re nata (PRN) regimen in Chinese patients with neovascular age-related macular degeneration (nAMD).MethodsThis was a randomized, multicenter, non-
Huixun Jia +22 more
doaj +2 more sources
Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy [PDF]
Ophthalmology and Therapy, 2023 Introduction To evaluate the real-world efficacy of aflibercept using the treat-and-extend (TnE) regimen in treating neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), and to analyze biomarkers using optical ...
Chu-Hsuan Huang +3 more
doaj +2 more sources
Five-year outcome of aflibercept intravitreal injection in naïve patients with neovascular age-related macular degeneration using a modified treat-and-extend regimen: Results from a prospective observational study [PDF]
Taiwan Journal of Ophthalmology, 2023 PURPOSE: The purpose is to study the 5-year results of aflibercept monotherapy using an individualized regimen in naïve patients with neovascular AMD (nAMD). MATERIALS AND METHODS: This is a prospective observational study including naïve nAMD patients
Jarret Charles, TRAN Thi Ha Chau
doaj +2 more sources
Clinical Outcomes of a Treat and Extend Regimen with Intravitreal Aflibercept Injections in Patients with Diabetic Macular Edema: Experience in Clinical Practice [PDF]
Ophthalmology and Therapy, 2019 Introduction Treat-and-extend (T&E) and pro re nata (PRN; ‘as needed’) regimens of intravitreal anti-vascular endothelial growth factor (VEGF) treatment have been found to reduce the injection burden on patients and improve the cost effectiveness of the ...
Beverley A. Curry +4 more
doaj +4 more sources
Aflibercept for central retinal vein occlusions: long-term outcomes of a 'Treat-and-Extend' regimen. [PDF]
BMJ Open OphthalmolBackground/aims This study reports on the long-term functional and anatomical outcomes of patients with central retinal vein occlusion (CRVO) treated under the Bern treat-and-extend (T&E) protocol. Methods Observational study.
Jaggi D +4 more
europepmc +4 more sources